Bio-Rad Laboratories Reports Increase in Q3 Non-GAAP Earnings and Revenue
- Earnings Report: Bio-Rad Laboratories (BIO) announced Q3 non-GAAP earnings of $2.26 per diluted share.
- Access Requirement: Users need to sign in to access their portfolio information.
Trade with 70% Backtested Accuracy
Analyst Views on BIO.B
About BIO.B
About the author
3 Stocks Signaling 'Buy' Opportunities for Investors Based on Technical Analysis
Market Volatility and Technical Analysis: Amid market fluctuations, investors can leverage technical analysis to identify promising stock opportunities, with TipRanks highlighting Wintrust Financial, Bio-Rad Laboratories, and Agree Realty as Strong Buy candidates.
Wintrust Financial Overview: Wintrust Financial is experiencing an upward trend, supported by a Strong Buy rating and 12 bullish signals indicating strong momentum according to TipRanks’ technical analysis.
Bio-Rad Laboratories Insights: Bio-Rad Laboratories also holds a Strong Buy consensus, with a positive Rate of Change (ROC) of 1.69, suggesting upward momentum and a Buy signal for the stock.
Agree Realty Corporation Analysis: Agree Realty is rated a Strong Buy based on moving average consensus, with a positive ROC of 2.75, indicating strong upward momentum and a favorable Buy signal.
Bio-Rad Laboratories Reports Increase in Q3 Non-GAAP Earnings and Revenue
- Earnings Report: Bio-Rad Laboratories (BIO) announced Q3 non-GAAP earnings of $2.26 per diluted share.
- Access Requirement: Users need to sign in to access their portfolio information.
BIO Surpasses Average Analyst Expectations
Current Stock Performance: Bio-Rad Laboratories Inc's shares have surpassed the average analyst 12-month target price of $331.40, trading at $333.97/share, prompting potential analyst reactions regarding valuation adjustments.
Analyst Target Range: Within the Zacks coverage universe, analyst targets for Bio-Rad vary significantly, with one analyst setting a low target of $265.00 and another as high as $437.00, indicating a standard deviation of $68.171.
Investor Considerations: The crossing of the average target price signals investors to evaluate whether the stock is on a trajectory towards higher targets or if it has become overvalued, suggesting a potential need to reassess their positions.
Analyst Ratings Overview: The article references a rating scale from 1 (Strong Buy) to 5 (Strong Sell) for Bio-Rad, reflecting the collective insights of analysts covering the company.
Now is the moment to acquire undervalued stocks in this essential economic sector.
High Valuations: Most U.S. stock sectors are trading at elevated valuations compared to expected earnings, indicating a potentially overvalued market.
S&P 500 Concentration: The S&P 500 index, which is heavily weighted by market capitalization, has led to high concentration among a few large-cap stocks, contributing to its expensive nature.
Market Perspective: Julien Albertini, a portfolio manager, emphasizes that the overall U.S. stock market is not cheap, with certain segments being particularly overpriced.
Investment Implications: Investors in index funds tied to the S&P 500 have seen success, but the high valuations raise concerns about future performance and market sustainability.
Bio-Rad Scheduled to Release Q3 2025 Financial Results on Wednesday, October 29, 2025
Financial Results Announcement: Bio-Rad Laboratories will report its Q3 2025 financial results on October 29, 2025, after market close, followed by a conference call at 2:00 PM PT.
Participation Details: Interested parties can join the conference call by dialing specific numbers or accessing a live webcast available on the company's Investor Relations website.
Analysts Predict 10% Growth for SCHX Holdings
ETF Analysis: The Schwab US Large-Cap ETF (SCHX) has an implied analyst target price of $29.19 per unit, indicating a potential upside of 9.86% from its recent trading price of $26.57.
Notable Holdings: Key underlying holdings with significant upside potential include TD SYNNEX Corp (11.60% upside), Bio-Rad Laboratories Inc (10.24% upside), and Lamar Advertising Co (9.98% upside) based on their respective analyst target prices.
3 Stocks Signaling 'Buy' Opportunities for Investors Based on Technical Analysis
Market Volatility and Technical Analysis: Amid market fluctuations, investors can leverage technical analysis to identify promising stock opportunities, with TipRanks highlighting Wintrust Financial, Bio-Rad Laboratories, and Agree Realty as Strong Buy candidates.
Wintrust Financial Overview: Wintrust Financial is experiencing an upward trend, supported by a Strong Buy rating and 12 bullish signals indicating strong momentum according to TipRanks’ technical analysis.
Bio-Rad Laboratories Insights: Bio-Rad Laboratories also holds a Strong Buy consensus, with a positive Rate of Change (ROC) of 1.69, suggesting upward momentum and a Buy signal for the stock.
Agree Realty Corporation Analysis: Agree Realty is rated a Strong Buy based on moving average consensus, with a positive ROC of 2.75, indicating strong upward momentum and a favorable Buy signal.
Bio-Rad Laboratories Reports Increase in Q3 Non-GAAP Earnings and Revenue
- Earnings Report: Bio-Rad Laboratories (BIO) announced Q3 non-GAAP earnings of $2.26 per diluted share.
- Access Requirement: Users need to sign in to access their portfolio information.
BIO Surpasses Average Analyst Expectations
Current Stock Performance: Bio-Rad Laboratories Inc's shares have surpassed the average analyst 12-month target price of $331.40, trading at $333.97/share, prompting potential analyst reactions regarding valuation adjustments.
Analyst Target Range: Within the Zacks coverage universe, analyst targets for Bio-Rad vary significantly, with one analyst setting a low target of $265.00 and another as high as $437.00, indicating a standard deviation of $68.171.
Investor Considerations: The crossing of the average target price signals investors to evaluate whether the stock is on a trajectory towards higher targets or if it has become overvalued, suggesting a potential need to reassess their positions.
Analyst Ratings Overview: The article references a rating scale from 1 (Strong Buy) to 5 (Strong Sell) for Bio-Rad, reflecting the collective insights of analysts covering the company.
Now is the moment to acquire undervalued stocks in this essential economic sector.
High Valuations: Most U.S. stock sectors are trading at elevated valuations compared to expected earnings, indicating a potentially overvalued market.
S&P 500 Concentration: The S&P 500 index, which is heavily weighted by market capitalization, has led to high concentration among a few large-cap stocks, contributing to its expensive nature.
Market Perspective: Julien Albertini, a portfolio manager, emphasizes that the overall U.S. stock market is not cheap, with certain segments being particularly overpriced.
Investment Implications: Investors in index funds tied to the S&P 500 have seen success, but the high valuations raise concerns about future performance and market sustainability.
Bio-Rad Scheduled to Release Q3 2025 Financial Results on Wednesday, October 29, 2025
Financial Results Announcement: Bio-Rad Laboratories will report its Q3 2025 financial results on October 29, 2025, after market close, followed by a conference call at 2:00 PM PT.
Participation Details: Interested parties can join the conference call by dialing specific numbers or accessing a live webcast available on the company's Investor Relations website.
Analysts Predict 10% Growth for SCHX Holdings
ETF Analysis: The Schwab US Large-Cap ETF (SCHX) has an implied analyst target price of $29.19 per unit, indicating a potential upside of 9.86% from its recent trading price of $26.57.
Notable Holdings: Key underlying holdings with significant upside potential include TD SYNNEX Corp (11.60% upside), Bio-Rad Laboratories Inc (10.24% upside), and Lamar Advertising Co (9.98% upside) based on their respective analyst target prices.
